|
|
|
|
|
|
Sponsored by: |
Alcon Research |
Information provided by: | Alcon Research |
ClinicalTrials.gov Identifier: | NCT00631358 |
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
Condition | Intervention | Phase |
Sjogren's Syndrome |
Drug: 0.1% Dexamethasone (Maxidex) |
Phase IV |
MedlinePlus related topics: | Sjogren's Syndrome |
Drug Information available for: | Dexamethasone Dexamethasone acetate Dexamethasone Sodium Phosphate Doxiproct plus |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment |
Estimated Enrollment: | 90 |
Study Start Date: | February 2008 |
Estimated Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: No Intervention
No treatment
|
|
2: Active Comparator
Treatment with Maxidex
|
Drug: 0.1% Dexamethasone (Maxidex)
Anti-inflammatory Agent
|
Ages Eligible for Study: | 17 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria of Sjorgren's Population:
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Alcon ( Ravaughn Williams, OD, MS ) |
Study ID Numbers: | ORE 14351 |
First Received: | February 29, 2008 |
Last Updated: | February 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00631358 |
Health Authority: | Canada: Health Canada; Canada: Institutional Ethics Committee |
|
|
|
|
|